IBD
Conditions
Interventions
ADA dose interval lengthened from 2 weeks to 3 weeks
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age 18 or older Written informed consent. Previous diagnosis of ileocolonic Crohn*s disease or ulcerative colitis In sustained clinical remission for at least 6 months whilst being treated with adalimumab Adalimumab dosed at 40mg, once every 2 weeks Full clinical response and disease control, defined as -Absence of intestinal or extra-intestinal symptoms, as judged by both patient and physician -Fecal calprotectin
Exclusion criteria
Exclusion criteria: Imminent need for IBD-related surgery Actively draining perianal fistula Pregnancy or lactation Other significant medical illness that might interfere with this study (such as current malignancy, immunodeficiency syndromes and psychiatric illness)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| -Relapse rates in both groups, defined by increase of fecal calprotectin and/or CRP and clinical activity, and subsequently confirmed by endoscopy -Tolerability | — |
Primary
| Measure | Time frame |
|---|---|
| Patients in remission after 24 weeks | — |
Countries
Netherlands
Outcome results
None listed